| Pharmaceutical Biology | |
| Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway | |
| Yan-Bo Sui1  Li Liu1  Yi-Qing Zhang2  Yu Wang3  Feng Liu4  | |
| [1] First Unit of Department of Cardiology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China;Fourth Unit of Department of Cardiology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Chin;Heilongjiang University of Chinese Medicine, Harbin, China;Third Unit of Department of Cardiology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China; | |
| 关键词: Left coronary artery ligation; CD31; VEGF; RNA interference; | |
| DOI : 10.1080/13880209.2019.1569697 | |
| 来源: Taylor & Francis | |
PDF
|
|
【 摘 要 】
Context: Heart failure (HF) is one of the most serious diseases worldwide. Astragaloside IV (ASI) is widely used for the treatment of cardiovascular disease in China.Objective: To evaluate the protective effect of ASI on the HF in a Sprague–Dawley rat model of left coronary artery ligation, and investigate the angiogenesis-related mechanisms.Materials and methods: Left coronary artery was ligated to induce a rat model of HF, and the rats were treated with vehicle (saline) or different doses of ASI (0.1, 0.3 and 1 mg/kg/day) by oral gavage for 6 weeks. Cardiac function was evaluated by echocardiography. Infarct size was determined by triphenyltetrazolium chloride staining. Cardiac vascular density was analyzed by microangiography. Real-time PCR, Western blot and chromatin immunoprecipitation were performed to investigate the mechanisms.Results: ASI treatment improved the body weight and survival rate of HF rats, as well as the cardiac function of HF rats, with significantly improved ejection fraction (75.27 ± 5.75% vs. 36.26 ± 4.14%) and fractional shortening (45.39 ± 3.66% vs. 17.88 ± 1.32%). ASI reduced the infarct size of the HF rats by 47%. ASI promoted angiogenesis, with increased vascular density (2.08-fold) and induced mRNA expression of CD31 (1.81-fold) and VEGF (2.70-fold) in the ischemic heart. Furthermore, ASI induced the phosphorylation of JAK (1.89-fold) and STAT3 (2.95-fold), as well as the activity of VEGF promoter which was regulated by STAT3.Discussion and conclusions: ASI alleviated HF by promoting angiogenesis through JAK-STAT3 pathway, providing novel alternative strategies to prevent HF in the future.
【 授权许可】
CC BY
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202111260032266ZK.pdf | 1430KB |
PDF